Phenotypes Associated with This Genotype

Genotype
MGI:5800410

• Allelic Composition: Tg(PDGFB-LRRK2*R1441C)31Hlw/0
• Genetic Background: FVB/N-Tg(PDGFB-LRRK2*R1441C)31Hlw

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

behavior/neurological

decreased vertical activity ( J:229559 )

• reduction in rears at 16 and 20 months of age

• treatment of 18 month old mutants with L-DOPA reverses the reduced rearing activity

bradykinesia ( J:229559 )

• mice exhibit an age-dependent and progressive slowness of motor activity, with velocity and distance of locomotion activity in the open field significantly declining in 16-20 month old mutants

nervous system

nervous system phenotype ( J:229559 )

N • Lewy bodies, Lewy neurites, or hyperphosphorylated tau are not seen in the brain of 16 month old mice

loss of dopaminergic neurons ( J:229559 )

• decrease in the number of substantia nigra pars compacta TH-positive dopaminergic neurons at 16, but not 12, months of age

• decrease in the number of Nissl-positive cells in the substantia nigra pars compacta at 16 months of age

• however, significant neuronal death is not seen in the cerebral cortex, hippocampus, and striatum at 16 months of age

abnormal synaptic bouton morphology ( J:229559 )

• mice show loss of dopaminergic terminals in the striatum

abnormal synaptic dopamine release ( J:229559 )

• mice exhibit decreased peak magnitude of dopamine oxidation current in dorsolateral striatal slices, indicating an impairment of evoked dopamine release from nigrostriatal dopaminergic terminals in the striatum at 16 months of age

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
Parkinson's disease 8		DOID:0060371	OMIM:607060	J:229559